In July, ICVBM will begin enrolling patients in the Angiogenic GENe Therapy (AGENT 3) trial under the direction of Dr.
If you would like to learn more about participating in the AGENT 3 trial at ICVBM, contact Julie Lacy, R.N., B.S.N., Clinical Research Coordinator, Indiana Center for Vascular Biology and Medicine, 975 West Walnut St., IB441, Indianapolis, IN 46202 or call 317-962-0138.
Current findings of the ICVBM
group complement new guidelines urging Americans--especially diabetics and others at high risk of heart disease--to lower LDL cholesterol levels.
In July, ICVBM
will begin enrolling patients in the AGENT trial under the direction of Dr.
Meldrum, an assistant professor in the departments of surgery and physiology at Indiana University School of Medicine and an ICVBM
Shankar, who, with colleagues at ICVBM
, is investigating the potential connection between metabolism and vascular function.
March at 317-278-0130, or e-mail: firstname.lastname@example.org ICVBM
's Web site is: iupui.edu/~icvbm.
Frank Witzmann, ICVBM
researcher and professor of cellular and integrative physiology at Indiana University School of Medicine.
Keith March, director of ICVBM
, urge more patients to enter the trial.
Breall, who joined the Krannert Institute of Cardiology at IU School of Medicine and the Indiana Center for Vascular Biology and Medicine (ICVBM
) three years ago.
Keith March is director of the Indiana Center for Vascular Biology and Medicine (ICVBM
) at the IU School of Medicine.
Tapping into the latest developments in genetic research and molecular biology, ICVBM
is committed to being a leader in basic and applied research to develop a greater understanding of--and novel therapies for--heart and other vascular related problems.